AKRO Akero Corp: Price-to-Projected Revenue Ratio

Akero Therapeutics - graphic logo of issuer AKRO

Akero Therapeutics (AKRO) aims to commercialize innovative treatments for steatohepatitis while remaining in the clinical trial stage. The strategy relies on close collaboration with hepatologists to establish proprietary standards of care. The expert team is actively expanding through stock options and the recruitment of specialized professionals. The forward P/S history helps assess the market value of future sales, while shows the current value of the metric.

Akero - AKRO Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/16/2026)

Summary analytical data breakdowns for Akero Therapeutics (AKRO)

- market price and analyst price targets:
- company stock capitalization data:
Fundamental company analysis:AKRO (Akero Therapeutics, Inc.)
Original product of Akero Corp

Akero Therapeutics (AKRO) is developing targeted MASH therapy, where the business valuation is based on the commercialization potential of efruxifermin and its attractiveness for M&A. The company's forward P/S reflects a market premium over expected sales, measuring investors' willingness to pay a premium for future revenue growth; an analysis of the company's forward P/S allows for the identification of asset overvaluation risks should the drug's development pace slow.

Competitors of Akero Therapeutics

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Madrigal Corp (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|MTSR: Forward P/S Multiple|MLTX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Crinetics Corp|NewAmsterdam Pharma Corp (NAMS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio soleno.life (SLNO)|Forward Price-to-Revenue Multiple Amicus Therapeutics FOLD|Forward Price to Sales 89bio Inc|Forward P/S Multiple Agios Pharmaceuticals, Inc. AGIO|GPCR: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio MiMedx Corp MDXG|RZLT (Rezolute Corp) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue LXRX|MBX (MBX Biosciences) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Altimmune Inc (ALT)|Forward Price-to-Revenue Multiple AARD (Aardvark Therapeutics Corp)|Forward Price-to-Revenue Multiple Sagimet SGMT|Forward P/S Multiple BIOA (BioAge Labs)|Forward P/S Multiple Biomea Fusion BMEA|QNCX: Forward Price-to-Revenue Multiple|GUTS: Price-to-Projected Revenue Ratio|vTv Therapeutics Inc (VTVT) - Price-to-Projected Revenue Ratio|ATPC: Price to Expected Revenue Ratio|PLUR (pluri-biotech.com) - Forward P/S Multiple|SYBX: Forward Price to Sales|Forward P/S Multiple LPCN|Market Cap to Expected Sales Ratio Matinas BioPharma Holdings, Inc.|Price-to-Projected Revenue Ratio Spruce Biosciences Inc. SPRB|GLTO - Forward Price-to-Revenue Multiple|CTCX - Price-to-Projected Revenue Ratio|LUMO - Forward P/S Multiple|ONVO: Forward P/S Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio